International Immunopharmacology

metrics 2024

Empowering Discoveries in Immunology and Pharmacological Applications

Introduction

International Immunopharmacology, published by Elsevier, stands as a prominent journal within the disciplines of immunology and pharmacology. With an ISSN of 1567-5769 and an E-ISSN of 1878-1705, this esteemed journal is based in the Netherlands and features a robust commitment to disseminating high-quality research from its inception in 2001 through 2024. The journal has achieved impressive rankings, securing a Q1 category in Pharmacology and Q2 in both Immunology and Immunology and Allergy as of 2023. With its strategic focus on bridging the gap between immunology and pharmacological applications, International Immunopharmacology attracts a diverse readership, including researchers, healthcare professionals, and students interested in the latest advancements in therapeutic agents and immune system modulation. Furthermore, it offers an open access option, enhancing the accessibility and reach of its invaluable content. As a pivotal resource in the field, this journal not only facilitates the exchange of innovative ideas but also fosters a deeper understanding of the complexities of immunopharmacology in today’s research landscape.

Metrics 2024

SCIMAGO Journal Rank1.17
Journal Impact Factor4.80
Journal Impact Factor (5 years)5.00
H-Index149
Journal IF Without Self4.80
Eigen Factor0.03
Normal Eigen Factor7.25
Influence0.93
Immediacy Index0.90
Cited Half Life3.90
Citing Half Life5.80
JCI1.24
Total Documents10850
WOS Total Citations33221
SCIMAGO Total Citations97046
SCIMAGO SELF Citations4444
Scopus Journal Rank1.17
Cites / Document (2 Years)4.99
Cites / Document (3 Years)5.20
Cites / Document (4 Years)5.24

Metrics History

Rank 2024

Scopus

Pharmacology in Pharmacology, Toxicology and Pharmaceutics
Rank #60/313
Percentile 80.83
Quartile Q1
Immunology and Allergy in Medicine
Rank #61/233
Percentile 73.82
Quartile Q2
Immunology in Immunology and Microbiology
Rank #72/236
Percentile 69.49
Quartile Q2

IF (Web Of Science)

IMMUNOLOGY
Rank 51/181
Percentile 72.10
Quartile Q2
PHARMACOLOGY & PHARMACY
Rank 50/354
Percentile 86.00
Quartile Q1

JCI (Web Of Science)

IMMUNOLOGY
Rank 32/181
Percentile 82.32
Quartile Q1
PHARMACOLOGY & PHARMACY
Rank 52/354
Percentile 85.31
Quartile Q1

Quartile History

Similar Journals

IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY

Elevating Knowledge in Immunopharmacology and Toxicological Science
Publisher: TAYLOR & FRANCIS LTDISSN: 0892-3973Frequency: 4 issues/year

Immunopharmacology and Immunotoxicology, published by Taylor & Francis Ltd, is a distinguished academic journal with a focus on the interrelation between pharmacology, immunology, and toxicology. Established in 1978, the journal serves as a vital platform for the dissemination of cutting-edge research aimed at enhancing the understanding of immunologically mediated drug responses and toxic effects. The journal encompasses a broad scope of topics relevant to the fields of immunology, pharmacology, and toxicology, offering insights that are pivotal for both academia and the pharmaceutical industry. With a commendable 2023 impact factor and ranking in Q3 in Immunology and Q2 in both Pharmacology and Toxicology, it holds a respected position within its categories, making it a valuable resource for researchers, professionals, and students seeking to stay abreast of the latest developments in the field. The journal is accessible through traditional subscription models and encourages submissions that bring forth innovative findings that might influence therapeutic strategies and public health.

INTERNATIONAL REVIEWS OF IMMUNOLOGY

Advancing the Frontiers of Immunological Research
Publisher: TAYLOR & FRANCIS INCISSN: 0883-0185Frequency: 6 issues/year

INTERNATIONAL REVIEWS OF IMMUNOLOGY, published by Taylor & Francis Inc, is a leading academic journal that has been a cornerstone of immunological research since its inception in 1986. With an impressive impact factor and ranked in the top quartiles of its field (Q2 in both Immunology and Allergy), this journal offers a critical platform for the dissemination of influential findings and advancements within immunology. Spanning a diverse array of topics, from basic immune mechanisms to clinical applications, it aims to support the global scientific community in enhancing immunological understanding and therapeutic interventions. Researchers and professionals alike benefit from insights provided by renowned contributors, ensuring that the journal remains relevant in a rapidly evolving field. Directly accessible through subscription or institutional access, INTERNATIONAL REVIEWS OF IMMUNOLOGY is committed to fostering collaboration and innovation, making it an essential resource for anyone involved in immunological research and practice.

CNS & Neurological Disorders-Drug Targets

Driving Change in Neurology through Open Access Research
Publisher: BENTHAM SCIENCE PUBLISSN: 1871-5273Frequency: 8 issues/year

CNS & Neurological Disorders-Drug Targets is a distinguished journal that focuses on contemporary research and advancements in the realms of neurology, pharmacology, and drug development. Published by Bentham Science Publishers, this journal serves as an essential platform for researchers, professionals, and students interested in the intricate workings of the central nervous system and the evolving strategies to target neurological disorders through pharmacological innovations. With a robust impact factor reflecting its academic relevance, CNS & Neurological Disorders-Drug Targets is categorized in the Q2 quartile for both Medicine (miscellaneous) and Pharmacology, and Q3 for Neuroscience in the 2023 rankings. The journal's Scopus rankings further reinforce its authority, positioning it within the top half of its categories. Operating out of the United Arab Emirates, the journal has been a loyal contributor to the scientific discourse since its inception in 2006 and will continue until at least 2024, ensuring a dynamic channel for the latest findings and reviews in this vital field. As an open-access publication, it prioritizes accessibility, thus fostering a wider impact among scholars and practitioners alike, making it a valuable resource for all stakeholders in neurological and pharmacological research.

JOURNAL OF REPRODUCTIVE IMMUNOLOGY

Unveiling the complexities of reproductive immunology.
Publisher: ELSEVIER IRELAND LTDISSN: 0165-0378Frequency: 6 issues/year

The JOURNAL OF REPRODUCTIVE IMMUNOLOGY, published by Elsevier Ireland Ltd, stands as a pivotal platform for exploring the intricate interactions between reproductive health and the immune system. With an ISSN of 0165-0378 and an E-ISSN of 1872-7603, this esteemed journal spans over four decades, from 1979 to 2024, contributing significantly to the fields of Immunology, Reproductive Medicine, and Obstetrics and Gynecology. Currently ranked in Q2 for Immunology and Allergy and Q1 for both Obstetrics and Gynecology and Reproductive Medicine, it serves as an invaluable resource for researchers, professionals, and students dedicated to advancing knowledge in reproductive health. The journal’s notable impact factor and rigorous peer-review process underscore its commitment to high-quality research, making it an essential reference point for ongoing studies in this ever-evolving discipline. By promoting interdisciplinary discussions and pioneering research findings, the JOURNAL OF REPRODUCTIVE IMMUNOLOGY fosters a deeper understanding of the immune mechanisms that influence reproductive outcomes.

CRITICAL REVIEWS IN IMMUNOLOGY

Advancing the Frontiers of Immune Science
Publisher: BEGELL HOUSE INCISSN: 1040-8401Frequency: 6 issues/year

CRITICAL REVIEWS IN IMMUNOLOGY, published by BEGELL HOUSE INC, is an essential journal in the field of immunology that has been contributing to the scientific discourse since 1980. With its ISSN 1040-8401 and E-ISSN 2162-6472, this journal provides a platform for critical analysis and comprehensive reviews that deepen understanding of immune responses and their implications in health and disease. Although currently categorized in the Q4 quartile for Immunology and Q3 for Immunology and Allergy, the journal's quality research and scholarly contributions are crucial for advancing knowledge within its fields—encompassing various aspects of innate and adaptive immunity. Researchers and professionals in immunology will find invaluable insights, aiding them in their quest for innovation and excellence, as the journal aims to foster interdisciplinary collaboration. While it does not operate on an open-access model, CRITICAL REVIEWS IN IMMUNOLOGY remains a significant resource for those dedicated to pushing the boundaries of immunology, with annual publications expected to last well into 2024 and beyond.

MOLECULAR ASPECTS OF MEDICINE

Advancing the Frontiers of Molecular Medicine
Publisher: ELSEVIERISSN: 0098-2997Frequency: 6 issues/year

MOLECULAR ASPECTS OF MEDICINE is a premier journal published by Elsevier, focusing on groundbreaking research in the fields of biochemistry, molecular biology, and medicine. With an impressive impact factor and ranking within the top quartile across multiple categories, including Q1 in Biochemistry, Clinical Biochemistry, and Molecular Medicine, it serves as an essential platform for sharing innovative findings that advance our understanding of molecular mechanisms in health and disease. The journal, which has been in publication since 1976, provides a diverse range of articles, addressing both fundamental and applied aspects of molecular medicine, thus appealing to a broad audience of researchers, professionals, and students. While MOLECULAR ASPECTS OF MEDICINE does not currently offer Open Access options, it remains a vital resource for accessing high-quality, peer-reviewed scholarly works that significantly contribute to the advancement of biomedical research.

Journal of Neuroimmune Pharmacology

Bridging Neuroscience and Immunology for Future Therapies
Publisher: SPRINGERISSN: 1557-1890Frequency: 4 issues/year

The Journal of Neuroimmune Pharmacology, published by Springer, is a premier academic journal dedicated to advancing the field of pharmacology intersecting with neuroscience and immunology. With an outstanding impact factor and proudly positioned in the Q1 quartile across multiple categories, this journal showcases cutting-edge research that enhances our understanding of the neuroimmune system and its pharmacological implications. Established in 2006 and continuing through 2024, it serves as a vital resource for researchers, professionals, and students alike, offering insights into the mechanisms of drug action, disease processes, and therapeutic strategies. As a testament to its excellence, the journal ranks prominently in Scopus metrics within its discipline, making it an essential platform for disseminating high-quality research that drives innovation in immunology, allergy, neuroscience, and pharmacology.

PARASITE IMMUNOLOGY

Innovative Insights into Immunology and Parasitology.
Publisher: WILEYISSN: 0141-9838Frequency: 12 issues/year

PARASITE IMMUNOLOGY, published by Wiley, is a leading journal in the field of immunology and parasitology, with an ISSN of 0141-9838 and E-ISSN of 1365-3024. Since its inception in 1979, it has played a pivotal role in advancing our understanding of host-parasite interactions, immunological responses to parasitic infections, and the mechanisms of immunological resistance. The journal is adeptly positioned within the academic community, currently holding a prestigious Q2 ranking in Parasitology and a Q3 ranking in Immunology for 2023, indicating its significant influence and relevance. Its comprehensive scope attracts a diverse readership, contributing to the discourse surrounding novel therapeutic approaches and emerging challenges in parasitic diseases. With a consistent convergence of research until 2024, PARASITE IMMUNOLOGY is an essential resource for researchers, professionals, and students seeking to deepen their knowledge and foster collaboration in these dynamic fields. Although it is not an open-access journal, the insights shared within its pages are invaluable for shaping future research trajectories.

Immunotherapy Advances

Transforming patient care through innovative immunotherapeutic insights.
Publisher: OXFORD UNIV PRESSISSN: Frequency: 1 issue/year

Immunotherapy Advances, published by Oxford University Press, stands at the forefront of the rapidly evolving field of immunology and microbe interactions, focusing specifically on novel immunotherapeutic strategies and their clinical applications. Established in 2021, this peer-reviewed journal aims to disseminate high-quality research that contributes to the understanding and advancement of immunotherapeutic techniques, potentially transforming patient care in immunology. With a current Scopus rank of #140 out of 236 in the realm of Immunology, placing it in the 40th percentile, Immunotherapy Advances is positioned to be an integral resource for researchers, healthcare professionals, and students eager to stay updated with groundbreaking findings and methodologies. The journal is dedicated to fostering innovative discussions and collaborations, ensuring open access to vital research that influences treatment paradigms globally.

IMMUNOLOGICAL INVESTIGATIONS

Navigating the Evolving Landscape of Immunological Investigations
Publisher: TAYLOR & FRANCIS INCISSN: 0882-0139Frequency: 8 issues/year

IMMUNOLOGICAL INVESTIGATIONS, published by Taylor & Francis Inc, is a leading journal in the field of immunology and related medical sciences, with an established presence since 1972. With a focus on cutting-edge research and critical insights in immunological methods and theories, this journal serves as a pivotal platform for researchers, professionals, and students alike. Though it currently holds a Q3 ranking in Immunology and a Q2 ranking in miscellaneous medicine as of 2023, its Scopus rank of #129 out of 236 reflects its dedication to advancing the understanding of immune responses and therapies. The journal's commitment to rigorous peer review and high-quality publications enables it to remain relevant and influential in the ever-evolving landscape of immunological research. Subscription is required to access its extensive archive, which spans critical developments in the field of immunology from 1972 to 2024.